Axonics Inc
NASDAQ:AXNX
Gross Margin
Axonics Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Axonics Inc
NASDAQ:AXNX
|
3.6B USD |
77%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
228B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.4B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
151.9B USD |
68%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.9B USD |
65%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
118B USD |
65%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.9B EUR |
39%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
55.9B USD |
45%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.3B USD |
62%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.1B USD |
79%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
41.5B USD |
59%
|
Axonics Inc
Glance View
Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Axonics Inc's most recent financial statements, the company has Gross Margin of 76.6%.
You don't have any saved screeners yet